Newbury Pharmaceuticals AB (publ) (STO:NEWBRY)
Sweden flag Sweden · Delayed Price · Currency is SEK
3.080
+0.020 (0.65%)
Apr 29, 2025, 5:08 PM CET

STO:NEWBRY Income Statement

Millions SEK. Fiscal year is Sep - Aug.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Feb '25 Aug '24 Aug '23 Aug '22 Aug '21
Revenue
41.4836.8310.275.523.09
Revenue Growth (YoY)
81.72%258.75%86.11%78.73%-
Cost of Revenue
21.4220.86.323.952.58
Gross Profit
20.0616.033.951.560.5
Selling, General & Admin
31.3428.7720.8114.665.95
Other Operating Expenses
-0.57---0.12-0.01
Operating Expenses
32.6430.522.0715.556.6
Operating Income
-12.58-14.47-18.12-13.99-6.1
Interest Expense
-1.77-1.53---0.04
Interest & Investment Income
0.20.20.16-0.11
Currency Exchange Gain (Loss)
0.390.39-1.47-0.68-0.03
Pretax Income
-13.64-15.41-19.43-14.67-6.06
Income Tax Expense
-0.23-0---
Net Income
-13.41-15.41-19.43-14.67-6.06
Net Income to Common
-13.41-15.41-19.43-14.67-6.06
Shares Outstanding (Basic)
24212018-
Shares Outstanding (Diluted)
24212018-
Shares Change (YoY)
21.82%9.68%9.68%--
EPS (Basic)
-0.56-0.72-1.00-0.82-
EPS (Diluted)
-0.56-0.72-1.00-0.82-
Gross Margin
48.36%43.53%38.46%28.35%16.26%
Operating Margin
-30.33%-39.29%-176.51%-253.57%-197.67%
Profit Margin
-32.33%-41.83%-189.28%-265.90%-196.43%
EBITDA
-11.62-13.65-17.78-13.89-
EBITDA Margin
-28.01%-37.05%-173.17%-251.87%-
D&A For EBITDA
0.960.820.340.09-
EBIT
-12.58-14.47-18.12-13.99-6.1
EBIT Margin
-30.33%-39.29%-176.51%-253.57%-197.67%
Revenue as Reported
39.7439.7411.177.243.1
Source: S&P Global Market Intelligence. Standard template. Financial Sources.